Business Wire
Welcome
  • Log In
  • Sign Up
Search News:
Help
http://www.pfizer.com
November 20, 2008 05:28 AM Eastern Time 

Pfizer Withdraws Application to Switch Viagra to Non-Prescription Status in Europe

NEW YORK--(BUSINESS WIRE)--Pfizer announced today that it has withdrawn its application to switch the legal status of the 50 mg tablet strength of Viagra from ‘prescription only’ to ‘non-prescription’ in the European Union (EU).

“Viagra has a proven safety profile that has been well established in extensive post-marketing studies and in more than 120 clinical trials”

Viagra is a well established oral medication for the treatment of erectile dysfunction (ED) and all current doses of Viagra will continue to be available to patients by prescription from their doctor.

Pfizer believes that Viagra 50 mg is a suitable candidate for non-prescription supply through pharmacists in the EU and meets the criteria set out by the European Commission guideline for changing the classification of a medicinal product to non-prescription. However, in a letter to the European Medicines Agency (EMEA), Pfizer said that it has decided to withdraw the application in order to fully consider comments from the EMEA’s Committee for Medicinal Products for Human Use (CHMP), recognizing that there were some concerns regarding the proposed supply of Viagra 50 mg tablets without a prescription in the EU. The CHMP noted that when Viagra is used in accordance with the currently approved prescribing information, its safety profile remains favorable. The withdrawal of the application will enable evaluation of further information and additional data that may be required to allow any future assessments under the centralized procedure.

Pfizer believes that access to Viagra 50 mg without a prescription in a pharmacy setting in the EU would provide valuable benefits to male patients suffering from ED. Millions of men in Europe are currently circumventing the healthcare system when seeking ED medicines, exposing themselves to unnecessary risks of medicines from uncontrolled sources and the missed opportunity to get important health information from a healthcare professional.

Since its introduction over a decade ago, Viagra has been used by more than 35 million men worldwide. “Viagra has a proven safety profile that has been well established in extensive post-marketing studies and in more than 120 clinical trials,” said Rory O’Connor, Pfizer vice president of Medical and Regulatory Affairs. “We will continue to work with regulators in Europe to improve the availability of our medicines to patients and physicians and the benefits they get from our therapies.”

Pfizer Inc: Working together for a healthier world™

Founded in 1849, Pfizer is the world's largest research-based pharmaceutical company taking new approaches to better health. We discover, develop, manufacture and deliver quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. We also partner with healthcare providers, governments and local communities around the world to expand access to our medicines and to provide better quality health care and health system support. At Pfizer, more than 80,000 colleagues in more than 90 countries work every day to help people stay happier and healthier longer and to reduce the human and economic burden of disease worldwide.

Contacts

Pfizer Inc
Media:
Lisa O’Neill, + 44 7967 756924
Lisa.O’Neill@pfizer.com
or
Oliver Stohlmann, + 43 664-335-0485
Oliver.stohlmann@pfizer.com
or
Investors:
Suzanne Harnett, 212-733-8009

Recent Stories from Pfizer Inc

  • View Press Release
    Pfizer Issues Statement On Voluntary Recall
    February 01, 2012
    Video
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today issued the following statement regarding the voluntary recall of Lo/Ovral®-28 (norgestrel and ethinyl estradiol): “We have announced a voluntary recall ... more »
  • View Press Release
    Pfizer Reports Fourth-Quarter and Full-Year 2011 Results; Updates 2012 Financial Guidance
    January 31, 2012
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE):   ($ in millions, except per share amounts)   Fourth-Quarter(3)   Year-to-Date(3) 2011   2010   Change 2011   2010   Change Reported Revenues $ 1... more »
  • View Press Release
    U.S. Food And Drug Administration Approves Pfizer’s INLYTA® (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
    January 27, 2012
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved INLYTA® (axitinib), a kinase inhibitor, for the treatment of patients with advan... more »
More Stories
RSS feed for Pfizer Inc
http://www.pfizer.com

Company Information Center

Pfizer Inc RSS feed for Pfizer Inc

NYSE:PFE

ISIN: US7170811035

Share

  • Facebook
  • Twitter
  • LinkedIn
  • Delicious
  • Reddit
  • StumbleUpon
  • Digg
  • MySpace
  • Newsvine
  • Google Bookmark
  • Yahoo! Bookmark
  • EmailEmail
Tweet
  • EmailEmail
All News
Business Wire
  • Home
    • Home
    • Membership Benefits
    • Submit a Press Release
  • News
    • All News
    • News with Multimedia
    • News by Industry
    • News by Subject
    • News by Language
    • RSS Feeds
    • Business Wire Mobile
    • Features
    • Company NewsCenters
    • Smart Marketing Pages
    • Company Profiles
    • Annual Reports
  • Events
    • Trade Shows & Events
    • Earnings & Conference Calls
    • Business Wire Events
  • PR Services
    • Press Release Distribution
    • Distribution Lists
    • Industry Targeting
    • LatinoWire & Ethnic Media
    • Public Policy Wire
    • Trade Show Services
    • Photos & Multimedia Marketing
    • GloMoSoMe
    • Press Release Measurement
    • Mobile Alerts
    • Clips & Research
    • Fax & Email Services
    • Online Newsrooms
    • News Feeds
  • IR Services
    • Material News Disclosure
    • XBRL
    • EDGAR (US)
    • IPO Services
    • SEDAR (Canada)
    • European Disclosure
    • Corporate Social Responsibility (CSR)
    • Investor Targeting
    • Fax & Email Services
    • Online Investor Centers
    • IR Resource Center
  • SEO Services
    • Press Release Optimization
    • EON: Enhanced Online News
    • Webinars & Resources
  • Journalist Tools
    • PressPass: Your News
    • Conduct Surveys
    • Business Wire News Feeds
    • Business Wire News On Your Website
    • Journalism Associations
  • Support & Education
    • FAQ
    • How to Write a Press Release
    • How To Optimize a Press Release for Search
    • How to Distribute a Press Release
    • Find Your News Online
    • Sample Press Release
    • Features News Tips
    • International Media Tips
    • SEC Regulations
    • Exchange Guidelines
    • White Papers
    • Webinars & Podcasts
    • Get WiredIn!
  • About Us
    • Business Wire Newsroom
    • Contact Us
    • History
    • Jobs
  • About Us
  • Contact Us
  • Site Map
  • Privacy Statement
  • Terms of Use
  • ©2012 Business Wire

More Business Wire sites

  • Canada
  • UK/Ireland
  • Deutschland
  • France
  • Italy
  • Japan
  • EON: Enhanced Online News
  • Tradeshownews.com
  • PYMNTS.com

About Us

  • Business Wire Newsroom
  • Contact Us
  • Business Wired blog

News on BusinessWire.com

  • All News
  • RSS Feeds
  • Business Wire Mobile Apps

Follow Us on Twitter

  • @BusinessWire
  • @BWSportsWire
  • @BWPolitics
  • @BWCSRNews
  • @EONpr
  • @TradeshowNews
  • @BW_Canada
  • @BWIntlMedia
  • @BWInfoDiva
  • @BusinessWireFR

Like Us on Facebook

  • Business Wire
  • Tradeshow News